TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8729628

Group type: EXPERIMENTAL
Intervention: Albendazole treatment (N = 49)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo (N = 48)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Infected group (N = 49)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Uninfected classmates (N = 48)
Number of subjects: 97
Study: 1824708

Group type: EXPERIMENTAL
Intervention: Nursing women who ovulated within 6 months postpartum
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Women with longer lactational amenorrhea
Number of subjects: 58

Group type: COMPARATOR
Intervention: Women with shorter lactational amenorrhea
Number of subjects: 58
Study: 7070255

Group type: EXPERIMENTAL
Intervention: Exposure to simulated altitude (barometric pressures of 681, 656, 632, and 574 mmHg simulating altitudes of 914, 1219, 1524, and 2286 m)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control altitude (362 m, barometric pressure = 730 mmHg)
Number of subjects: 12
Study: 30969962

Group type: EXPERIMENTAL
Intervention: Only children with overweight/obesity
Number of subjects: 1348

Group type: EXPERIMENTAL
Intervention: Only children
Number of subjects: 1348

Group type: COMPARATOR
Intervention: Peers with siblings
Number of subjects: 1348
Study: 29236722

Group type: EXPERIMENTAL
Intervention: Decision aid
Number of subjects: 1206

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1206
Study: 25880234

Group type: EXPERIMENTAL
Intervention: Community-based diabetes self-management education (DSME) intervention targeting empowerment
Number of subjects: 516

Group type: COMPARATOR
Intervention: Control group (six lectures on unrelated geriatrics topics)
Number of subjects: 516
Study: 22999262

Group type: EXPERIMENTAL
Intervention: Stress task (Trier Social Stress Test)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control task
Number of subjects: 46
Study: 22900437

Group type: EXPERIMENTAL
Intervention: Hand instruments
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Airotor
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Carisolv
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Papacarie
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 80
Study: 19563680

Group type: COMPARATOR
Intervention: no electronic games
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: traditional electronic games
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: active electronic games
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: all conditions
Number of subjects: 72
Study: 17044088

Group type: EXPERIMENTAL
Intervention: Neuromuscular therapy (NMT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Music relaxation (MR, active control)
Number of subjects: 36
Study: 15199082

Group type: EXPERIMENTAL
Intervention: Meloxicam (15 mg qd) for 4 days followed by aspirin (100 mg qd) for 7 days
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg qd) for 7 days after meloxicam
Number of subjects: 16

Group type: COMPARATOR
Intervention: Aspirin (100 mg) for 2 days
Number of subjects: 16
Study: 11778778

Group type: EXPERIMENTAL
Intervention: Abbreviated form of the Portland Digit Recognition Test (PDRT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Full scale Portland Digit Recognition Test (PDRT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Warned Simulators (control group)
Number of subjects: 80
Study: 9393424

Group type: EXPERIMENTAL
Intervention: Crestal incision (1,705 implants)
Number of subjects: 522

Group type: COMPARATOR
Intervention: Remote incision (593 implants)
Number of subjects: 522
Study: 7943676

Group type: EXPERIMENTAL
Intervention: 2-deoxy-D-glucose (2-DG) 25.0 mg/kg
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 2-deoxy-D-glucose (2-DG) 12.5 mg/kg
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 3370038

Group type: EXPERIMENTAL
Intervention: Intravenous administration of 0.5 mg/kg of indocyanine green (ICG) after 24 hours of head-down bed rest
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intravenous administration of 0.5 mg/kg of indocyanine green (ICG) after being seated for 1 hour
Number of subjects: 10
Study: 31648705

Group type: EXPERIMENTAL
Intervention: Evolocumab + Standard of Care (SOC)
Number of subjects: 1255

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 1255
Study: 28511584

Group type: EXPERIMENTAL
Intervention: Parent-focused intervention program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison condition
Number of subjects: 60
Study: 25590831

Group type: EXPERIMENTAL
Intervention: Synthetic mesh soaked in vancomycin solution (Group 2)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 52
Study: 23147209

Group type: EXPERIMENTAL
Intervention: rimonabant 20 mg/day
Number of subjects: 289

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 289
Study: 21519360

Group type: EXPERIMENTAL
Intervention: Arbaclofen placarbil (AP) 20 mg daily
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Arbaclofen placarbil (AP) 40 mg daily
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Arbaclofen placarbil (AP) 60 mg daily
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Arbaclofen placarbil (AP) 30 mg twice daily
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study: 19024539

Group type: EXPERIMENTAL
Intervention: Flexible cystoscope
Number of subjects: 112

Group type: COMPARATOR
Intervention: Rigid cystoscope
Number of subjects: 112
Study: 16480474

Group type: EXPERIMENTAL
Intervention: Propacetamol 2 g intravenously, 5 h apart (n = 40)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg intramuscularly (n = 40)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (n = 40)
Number of subjects: 120
Study: 12937335

Group type: EXPERIMENTAL
Intervention: skills training condition
Number of subjects: 118

Group type: COMPARATOR
Intervention: minimal support control condition
Number of subjects: 118
Study: 10729298

Group type: EXPERIMENTAL
Intervention: Nasal application of oxygen at a constant flow of 2 l/min
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ambient air at a constant flow of 2 l/min
Number of subjects: 40
Study: 9575599

Group type: EXPERIMENTAL
Intervention: Antioxidants
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 8222122

Group type: EXPERIMENTAL
Intervention: Enalapril (2.5 to 20 mg/d)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 3532605

Group type: EXPERIMENTAL
Intervention: New Rift Valley fever vaccine (formalin‐inactivated, prepared in diploid fetal rhesus lung cells)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Various vaccine lots
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional pre‐filtration or pre‐inactivation virus infectivity assays
Number of subjects: 0

Group type: COMPARATOR
Intervention: Animal potency tests
Number of subjects: 0
Study: 29426300

Group type: EXPERIMENTAL
Intervention: Oral calcitriol 0.5 mcg daily for 6 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Identically-matched placebo for 6 weeks
Number of subjects: 40
Study: 28861980

Group type: EXPERIMENTAL
Intervention: Gushen Antai pills combined with progesterone
Number of subjects: 112

Group type: COMPARATOR
Intervention: Progesterone (control group)
Number of subjects: 112
Study: 24683592

Group type: EXPERIMENTAL
Intervention: Paracore + polydopamine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Paracore + control
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: RelyX Unicem + polydopamine
Number of subjects: 40

Group type: COMPARATOR
Intervention: RelyX Unicem + control
Number of subjects: 40
Study: 23053639

Group type: EXPERIMENTAL
Intervention: ROLL (radioguided occult lesion localisation)
Number of subjects: 314

Group type: COMPARATOR
Intervention: WGL (wire-guided localisation)
Number of subjects: 314
Study: 20141567

Group type: EXPERIMENTAL
Intervention: Very low carbohydrate, high saturated fat diet (LC)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Isocaloric high carbohydrate, low fat diet (LF)
Number of subjects: 49
Study: 18677973

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate plus reproterol (DSCG/REP) inhalation 20 min before exercise challenge
Number of subjects: 24

Group type: COMPARATOR
Intervention: Montelukast (MON) oral treatment for 3 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate plus reproterol (DSCG/REP) adjusted
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate plus reproterol (DSCG/REP) unadjusted
Number of subjects: 24
Study: 15918822

Group type: EXPERIMENTAL
Intervention: Lidocaine 1.5% (Group E)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Saline (Group C)
Number of subjects: 19
Study: 12911187

Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study: 10561733

Group type: EXPERIMENTAL
Intervention: Perioperative administration of a serine protease inhibitor
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no serine protease inhibitor)
Number of subjects: 20
Study: 8572007

Group type: EXPERIMENTAL
Intervention: Antimicrobial therapy (ampicillin-sulbactam and amoxicillin-clavulanic acid)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 8297564

Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Hemofiltration (HF)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD) and Hemofiltration (HF)
Number of subjects: 9
Study: 31285376

Group type: EXPERIMENTAL
Intervention: Endovascular therapy under assumed ideal conditions
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Endovascular therapy under current local resources (night time scenarios)
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Endovascular therapy under current local resources (daytime scenarios)
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Endovascular therapy under assumed ideal conditions (daytime scenarios)
Number of subjects: 607

Group type: COMPARATOR
Intervention: Night time presentation
Number of subjects: 607
Study: 30513824

Group type: EXPERIMENTAL
Intervention: Reduced-gluten diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal-gluten diet
Number of subjects: 0
Study: 27388357

Group type: EXPERIMENTAL
Intervention: Eldecalcitol (active vitamin D analogue)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25608583

Group type: EXPERIMENTAL
Intervention: darunavir 600 mg/100 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: darunavir 800 mg/100 mg
Number of subjects: 16
Study: 24364448

Group type: EXPERIMENTAL
Intervention: Pedometers, motivational brochures, and Internet programme for 4 weeks
Number of subjects: 495

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 495
Study: 21708057

Group type: EXPERIMENTAL
Intervention: 70 mg of DHEAS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17702595

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus gemcitabine
Number of subjects: 259

Group type: COMPARATOR
Intervention: Control group (elderly patients)
Number of subjects: 259
Study: 16776915

Group type: EXPERIMENTAL
Intervention: Warfarin (adjusted-dose, INR 2.0 - 3.0)
Number of subjects: 704

Group type: COMPARATOR
Intervention: Aspirin (150 mg - 160 mg once daily)
Number of subjects: 704
Study: 12584227

Group type: EXPERIMENTAL
Intervention: lamivudine
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: interferon (IFN)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: IFN-lamivudine combination therapy
Number of subjects: 130
Study: 9880387

Group type: EXPERIMENTAL
Intervention: Early discharge to community therapy
Number of subjects: 274

Group type: COMPARATOR
Intervention: Conventional arm of the trial
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Therapy, meals on wheels, home help visits
Number of subjects: 274
Study: 7662102

Group type: EXPERIMENTAL
Intervention: Acardust
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 2678880

Group type: EXPERIMENTAL
Intervention: Low-dose oral contraceptives
Number of subjects: 20

Group type: COMPARATOR
Intervention: No oral contraceptives
Number of subjects: 20
Study: 794978

Group type: EXPERIMENTAL
Intervention: Mazindol (tricyclic compound, non-amphetamine) for 8 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo treatment for 8 weeks
Number of subjects: 20
Study: 30303612

Group type: EXPERIMENTAL
Intervention: Tramadol/Acetaminophen combination
Number of subjects: 1485

Group type: COMPARATOR
Intervention: Acetaminophen
Number of subjects: 1485

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1485
Study: 27791258

Group type: EXPERIMENTAL
Intervention: Femorally inserted venous catheters (FIVCs) with exit site at mid-thigh (NOV)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Femorally inserted venous catheters (FIVCs) with exit site at groin (CON)
Number of subjects: 114
Study: 26228621

Group type: EXPERIMENTAL
Intervention: Sealants applied to occlusal surfaces of primary molars
Number of subjects: 147

Group type: COMPARATOR
Intervention: Fluoride varnish applications
Number of subjects: 147
Study: 23706546

Group type: EXPERIMENTAL
Intervention: Intraperitoneal instillation of 100 mg bupivacaine in 100 mL normal saline solution
Number of subjects: 160

Group type: COMPARATOR
Intervention: Normal saline solution (placebo)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Intraperitoneal instillation of 100 mg bupivacaine
Number of subjects: 160
Study: 21210001

Group type: EXPERIMENTAL
Intervention: Maxcem
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Clearfil Esthetic Cement
Number of subjects: 20
Study: 19246041

Group type: EXPERIMENTAL
Intervention: Combined self-management and relaxation-breathing training
Number of subjects: 48

Group type: COMPARATOR
Intervention: Self-management-only training (Control)
Number of subjects: 48
Study: 16388958

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft and ventricular restoration (Group 1b, 39 patients)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Coronary artery bypass graft (Group 1a, 35 patients)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Coronary artery bypass graft and ventricular reconstruction (Group 2, 69 patients)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Mitral regurgitation grades 1 to 2+
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: End-systolic volume
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Heart failure class (NYHA)
Number of subjects: 137
Study: 15518637

Group type: EXPERIMENTAL
Intervention: Cervical spinal cord injury (SCI) subjects
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 31
Study: 11021956

Group type: EXPERIMENTAL
Intervention: telmisartan 80 mg
Number of subjects: 426

Group type: COMPARATOR
Intervention: valsartan 80 mg
Number of subjects: 426
Study: 9256871

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) at 20% of maximal inspiratory pressure (MIP) for 5 to 15 minutes, three times a day, for 8 weeks
Number of subjects: 14
Study: 7945125

Group type: EXPERIMENTAL
Intervention: Cinnarizine
Number of subjects: 179

Group type: COMPARATOR
Intervention: Scopolamine
Number of subjects: 179
Study: 3582722

Group type: EXPERIMENTAL
Intervention: 1000 mg amoxycillin twice daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: 750 mg amoxycillin three times daily
Number of subjects: 50
Study: 30144658

Group type: EXPERIMENTAL
Intervention: Presence of aggressive behaviors identified using the Korean interRAI Long‐Term Care Facility Assessment Tool.
Number of subjects: 1447

Group type: EXPERIMENTAL
Intervention: Social engagement as a contributing factor.
Number of subjects: 1447
Study: 27802417

Group type: EXPERIMENTAL
Intervention: Sodium nitrite (0.3 mg kg ‐1) after placebo
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sodium nitrite (0.3 mg kg ‐1) after esomeprazole (3×40 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sodium nitrite (1, 10, and 30 nmol kg ‐1 min ‐1) intravenously
Number of subjects: 15
Study: 26017285

Group type: EXPERIMENTAL
Intervention: Pulsatile double-compression-coated tablets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Core mini-tablets
Number of subjects: 0
Study: 23064732

Group type: EXPERIMENTAL
Intervention: Modified Pilates exercises (12 sessions over 6 weeks)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Education alone (control group)
Number of subjects: 86
Study: 21186984

Group type: EXPERIMENTAL
Intervention: triple therapy + kefir (n=46)
Number of subjects: 82

Group type: COMPARATOR
Intervention: triple therapy + placebo (n=36)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: triple therapy + kefir
Number of subjects: 82

Group type: COMPARATOR
Intervention: triple therapy + placebo
Number of subjects: 82
Study: 18679637

Group type: EXPERIMENTAL
Intervention: Topical preparation containing urea, vitamins, and ceramides for 2 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Topical urea-only preparation
Number of subjects: 10
Study: 16792302

Group type: EXPERIMENTAL
Intervention: Frequency-coded steady-state visual evoked potentials (VEP) based brain-computer interface
Number of subjects: 0
Study: 14572570

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Relaxation Therapy
Number of subjects: 105

Group type: COMPARATOR
Intervention: Routine Clinical Care
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: All treatment groups (CBT, Relaxation, Routine Care)
Number of subjects: 105
Study: 11198055

Group type: EXPERIMENTAL
Intervention: 5 mg d-amphetamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 mg d-amphetamine
Number of subjects: 0
Study: 9011451

Group type: EXPERIMENTAL
Intervention: Patients with muddy pigment stones (intervention group)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Patients without gallstones (control group)
Number of subjects: 208
Study: 1328400

Group type: EXPERIMENTAL
Intervention: 0.05% all-trans retinoic acid for 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low concentration of retinoic acid (10(‐11) M)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High concentration of retinoic acid (10(‐7) M)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Up to 10(‐7) M retinoic acid
Number of subjects: 0
Study: 6833677

Group type: EXPERIMENTAL
Intervention: Inhaled verapamil
Number of subjects: 15

Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Inhaled verapamil (before a single inhalation test)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 15
Study: 31607726

Group type: EXPERIMENTAL
Intervention: Conventional septoplasty (CS)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Endoscopic septoplasty (ES)
Number of subjects: 50
Study: 29576857

Group type: EXPERIMENTAL
Intervention: Naringenin (20 mg daily)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo (20 mg daily)
Number of subjects: 95
Study: 27088545

Group type: EXPERIMENTAL
Intervention: Systematic antimicrobial therapy for all episodes of AB occurring ≤24 months after transplantation (53 patients)
Number of subjects: 112

Group type: COMPARATOR
Intervention: No antimicrobial therapy (59 patients)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Systematic antimicrobial therapy for AB (26 patients, per-protocol)
Number of subjects: 112

Group type: COMPARATOR
Intervention: No antimicrobial therapy (50 patients, per-protocol)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Systematic screening and treatment of AB
Number of subjects: 112
Study: 24448046

Group type: EXPERIMENTAL
Intervention: Protected sleep periods (midnight to 3:00 AM and 3:00 to 6:00 AM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protected sleep periods (late shift)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protected sleep periods
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard intern schedule
Number of subjects: 0
Study: 21463799

Group type: EXPERIMENTAL
Intervention: Amino acid supplement (24 g of an oral supplement containing a leucine metabolite, glutamine, and arginine twice daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no amino acid supplement)
Number of subjects: 30
Study: 19539268

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Sham depletion
Number of subjects: 43
Study: 16936991

Group type: EXPERIMENTAL
Intervention: Group DE (hypocaloric diet + aerobic physical activity 1 hour/day 3 times a week)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Group D (hypocaloric diet only)
Number of subjects: 50
Study: 15133538

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bare metal stents
Number of subjects: 0
Study: 11117774

Group type: EXPERIMENTAL
Intervention: Vaginal clindamycin (one-week course)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 9068344

Group type: EXPERIMENTAL
Intervention: Mivacurium 0.6 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no mivacurium)
Number of subjects: 10
Study: 8453193

Group type: COMPARATOR
Intervention: Calcium 600 mg/day
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Calcium plus etidronate sodium 400 mg/day for 14 days every 3 months
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Calcium plus etidronate plus phosphate (1 g twice daily for 3 days before etidronate)
Number of subjects: 36
Study: 3458431

Group type: EXPERIMENTAL
Intervention: Epirubicin Regimen A (40‐60 mg/m2 every three weeks)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Epirubicin Regimen B (20‐30 mg/m2/day for 3 days every three weeks)
Number of subjects: 41
Study: 1176325

Group type: EXPERIMENTAL
Intervention: Proximal selective vagotomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Proximal selective vagotomy with pyloroplasty
Number of subjects: 50